Fosun Pharma advances drug trial for pediatric brain tumors

Shanghai Fosun Pharmaceutical Group announced that its subsidiary, Shanghai Fosun Pharmaceutical Industry Development, has commenced Phase III clinical trials in mainland China for FCNaming R (generic name: selumetinib tablets). The drug targets the treatment of pediatric low-grade gliomas. Selumetinib is an innovative small molecule chemical drug developed in-house, acting as a MEK1/2 selective inhibitor. The drug has already been approved in China for Langerhans cell histiocytosis (LCH) and histiocytic tumor adult patients, as well as Type I neurofibromatosis (NF1) in children and adolescents. As of May 2025, the cumulative research and development investment in the drug is approximately CNY 607 million. Global sales of MEK1/2 selective inhibitors reached USD 20.68 billion in 2024. Fosun Pharma cautioned that drug development involves inherent risks and uncertainties.